MDxHealth announced this morning that it had achieved a further US reimbursement milestone by obtaining a Category I CPT code for its prostate cancer diagnostic ConfirmMDx. This, together with the announcement last week of coverage of the product by the fourth largest US health insurer US Health Care Services Corporation (HCSC), should extend the reimbursement of ConfirmMDx in the US further strengthening the company's established commercial platform and ability to create substantial further value from its two follow on products exploiting substantial opportunities in the US, Europe and other international markets. We reiterate both our OUTPERFORM recommendation and target price of €6/share.
31 Oct 2016
Further US reimbursement milestone
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Further US reimbursement milestone
MDxHealth S.A. (0O8G:LON) | 0 0 0.3% | Mkt Cap: 168.5m
- Published:
31 Oct 2016 -
Author:
Chris Redhead -
Pages:
4
MDxHealth announced this morning that it had achieved a further US reimbursement milestone by obtaining a Category I CPT code for its prostate cancer diagnostic ConfirmMDx. This, together with the announcement last week of coverage of the product by the fourth largest US health insurer US Health Care Services Corporation (HCSC), should extend the reimbursement of ConfirmMDx in the US further strengthening the company's established commercial platform and ability to create substantial further value from its two follow on products exploiting substantial opportunities in the US, Europe and other international markets. We reiterate both our OUTPERFORM recommendation and target price of €6/share.